Kintegral Advisory LLC Sells 41,378 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Kintegral Advisory LLC reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 32.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 84,367 shares of the biopharmaceutical company's stock after selling 41,378 shares during the period. Bristol Myers Squibb comprises 0.8% of Kintegral Advisory LLC's investment portfolio, making the stock its 29th biggest position. Kintegral Advisory LLC's holdings in Bristol Myers Squibb were worth $5,146,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of BMY. Brighton Jones LLC grew its position in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG bought a new stake in Bristol Myers Squibb in the fourth quarter worth $13,094,000. Steward Partners Investment Advisory LLC boosted its position in Bristol Myers Squibb by 5.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 156,751 shares of the biopharmaceutical company's stock valued at $8,866,000 after buying an additional 7,624 shares during the period. Exencial Wealth Advisors LLC grew its stake in shares of Bristol Myers Squibb by 8.8% during the fourth quarter. Exencial Wealth Advisors LLC now owns 16,776 shares of the biopharmaceutical company's stock valued at $949,000 after buying an additional 1,353 shares during the last quarter. Finally, Souders Financial Advisors increased its holdings in shares of Bristol Myers Squibb by 9.6% in the fourth quarter. Souders Financial Advisors now owns 6,362 shares of the biopharmaceutical company's stock worth $360,000 after buying an additional 558 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction dated Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president directly owned 83,513 shares of the company's stock, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.09% of the stock is owned by insiders.

Bristol Myers Squibb Stock Down 1.3%

BMY stock traded down $0.62 during trading on Friday, hitting $47.02. 7,024,133 shares of the stock traded hands, compared to its average volume of 12,882,565. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The stock has a market cap of $95.68 billion, a price-to-earnings ratio of 17.61, a price-to-earnings-growth ratio of 1.39 and a beta of 0.36. Bristol Myers Squibb Company has a 1 year low of $39.35 and a 1 year high of $63.33. The firm's 50 day moving average is $47.73 and its two-hundred day moving average is $53.62.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the prior year, the firm posted ($4.40) EPS. The firm's quarterly revenue was down 5.6% on a year-over-year basis. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.27%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is presently 92.88%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BMY. Jefferies Financial Group reduced their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target for the company. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Finally, Wall Street Zen lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $58.00.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.